1 |
Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
|
2 |
Serdarevic NJ, Mehanovic S (2012). The possible role of tumor antigen CA 15-3, CEA and ferritin in malignant and benign disease. J Health Sci, 2, 138-43.
DOI
|
3 |
Thriveni K, Krishnamoorthy L, Ramaswamy G (2007). Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem, 22, 57-60.
DOI
ScienceOn
|
4 |
Tondini C, Hayes DF, Kufe DW (1989). Circulating tumor markers in breast cancer. Hematol/Onco Clin North Am, 3, 653-74.
|
5 |
Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al (2012). The application of current diagnostic protocols of patients with colon cancer in preparation for therapy. Acta Inform Med, 4, 238-41.
|
6 |
Zare M, Rezaee A, Zakiani SH, Zare A (2012). Study of Iranian breast cancer registration via established online system during 2011. IOS Press, 4, 1197-201.
|
7 |
Atoum M, Nimer N, Abdeldayem S, Nasr H (2012). Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 3, 857-60.
|
8 |
Barros AC, Fry W Jr, Nazario AC, Santos MO, Sato MK (1994). Experience with CA 15.3 as a tumor marker in breast cancer. Eur J Surg Oncol, 20, 130-3.
|
9 |
Begum M, Karim S, Malik A, et al (2012). CA15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 10, 5257-61.
|
10 |
Compton CC, Fielding LP, Burgart LJ, et al (2000). Prognostic factors in colorectal cancer. Arch Pathol Lab Med, 124, 979-94.
|
11 |
Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddigh Z (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev, 7, 571-4.
|
12 |
Dunnwald LK, Rossing MA, Li1 CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res, 9, 1-10.
|
13 |
Keyhani M, Nasizadeh S, Dehghannejad A (2005). Serum CA15-3 measurements in breast cancer patient before and after mastectomy. Arch Iranian Med, 4, 263-6.
|
14 |
Martoni A, Zamagni C, Bellanova B, et al (1995). CEA, MCA, CA15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer, 31, 1615-21.
DOI
ScienceOn
|
15 |
Duffy MJ (1989). New cancer markers. Ann Clin Biochem, 26, 379-87.
DOI
|
16 |
Duffy MJ (1999). CA15.3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 36, 579-86.
DOI
|
17 |
Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A (2009). Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal, 10, 521-4.
|